2.23
price up icon3.72%   0.08
 
loading

Aditxt Inc Borsa (ADTX) Ultime notizie

pulisher
May 02, 2025

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™ - Quantisnow

May 02, 2025
pulisher
May 02, 2025

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, - GuruFocus

May 02, 2025
pulisher
Apr 28, 2025

Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department - GuruFocus

Apr 28, 2025
pulisher
Apr 26, 2025

Aditxt secures $256K through senior note sales By Investing.com - Investing.com Nigeria

Apr 26, 2025
pulisher
Apr 25, 2025

Aditxt secures $256K through senior note sales - Investing.com

Apr 25, 2025
pulisher
Apr 22, 2025

Aditxt’s Subsidiary Pearsanta Gets IRB Approval - TipRanks

Apr 22, 2025
pulisher
Apr 18, 2025

Aditxt Delivers Shareholder Update and 2024 Year-End Plan - ADVFN

Apr 18, 2025
pulisher
Apr 17, 2025

Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™ - Quantisnow

Apr 17, 2025
pulisher
Apr 17, 2025

Pre-market Movers: RGC, SYRS, ADTX, ATXI... - RTTNews

Apr 17, 2025
pulisher
Apr 17, 2025

Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adim - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™ - Business Wire

Apr 17, 2025
pulisher
Apr 17, 2025

Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune - Bluefield Daily Telegraph

Apr 17, 2025
pulisher
Apr 16, 2025

Aditx Therapeutics Stock Hits 52-Week Low at $2.35 By Investing.com - Investing.com South Africa

Apr 16, 2025
pulisher
Apr 16, 2025

Aditx Therapeutics Stock Hits 52-Week Low at $2.35 - Investing.com Australia

Apr 16, 2025
pulisher
Apr 16, 2025

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025 | ADTX Stock News - GuruFocus

Apr 16, 2025
pulisher
Apr 16, 2025

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025 - Business Wire

Apr 16, 2025
pulisher
Apr 16, 2025

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Cl - GuruFocus

Apr 16, 2025
pulisher
Apr 15, 2025

Aditxt (ADTX) Study Reinforces ADI-100's Promise in Autoimmune T - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Aditxt Subsidiary Adimune Announces Positive Results from Mayo C - GuruFocus

Apr 15, 2025
pulisher
Apr 14, 2025

Aditxt Regains Nasdaq Compliance with Bid Price - TipRanks

Apr 14, 2025
pulisher
Apr 14, 2025

Aditxt announces results from ADI-100 study - TipRanks

Apr 14, 2025
pulisher
Apr 14, 2025

Aditxt Subsidiary Adimune Announces Positive Results From Mayo Clinic Pre-Clinical Studies To Support FDA And European Regulatory Submissions For Type 1 Diabetes, Psoriasis, And Stiff Person Syndrome Human Trials - marketscreener.com

Apr 14, 2025
pulisher
Apr 14, 2025

Aditxt (ADTX) Study Reinforces ADI-100's Promise in Autoimmune Treatments | ADTX Stock News - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Evofem Biosciences to Present at Emerging Growth Conference - Quantisnow

Apr 14, 2025
pulisher
Apr 14, 2025

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials - Business Wire

Apr 14, 2025
pulisher
Apr 12, 2025

Rhythm Pharmaceuticals (RYTM): Surge in Interest Following Positive Trial Results | ADTX Stock News - GuruFocus

Apr 12, 2025
pulisher
Apr 12, 2025

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements | ADTX Stock News - GuruFocus

Apr 12, 2025
pulisher
Apr 11, 2025

ADITXT Earnings Preview: Recent $ADTX Insider Trading, Hedge Fund Activity, and More - Nasdaq

Apr 11, 2025
pulisher
Apr 11, 2025

Aditxt regains Nasdaq compliance, updates on operations By Investing.com - Investing.com India

Apr 11, 2025
pulisher
Apr 11, 2025

Aditxt Weekly Update to Highlight Recent Events, Including Regai - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Aditxt regains Nasdaq compliance, updates on operations - Investing.com

Apr 11, 2025
pulisher
Apr 11, 2025

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements - Business Wire

Apr 11, 2025
pulisher
Apr 10, 2025

Why Aditxt Inc. (ADTX) Went Down On Thursday? - Insider Monkey

Apr 10, 2025
pulisher
Apr 10, 2025

Aditxt invests $1.5 million in Evofem amid merger talks By Investing.com - Investing.com India

Apr 10, 2025
pulisher
Apr 09, 2025

10 Stocks Fall Behind Amid Market Optimism - Insider Monkey

Apr 09, 2025
pulisher
Apr 09, 2025

Aditxt Enters Securities Purchase Agreement With Evofem BiosciencesSEC Filing - marketscreener.com

Apr 09, 2025
pulisher
Apr 09, 2025

Is Aditxt Shares’ Steep Decline a Buying Opportunity? - timothysykes.com

Apr 09, 2025
pulisher
Apr 09, 2025

Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listi - GuruFocus

Apr 09, 2025
pulisher
Apr 09, 2025

Aditxt regains Nasdaq compliance, cancels hearing By Investing.com - Investing.com India

Apr 09, 2025
pulisher
Apr 09, 2025

Aditxt regains Nasdaq compliance, cancels hearing - Investing.com

Apr 09, 2025
pulisher
Apr 09, 2025

Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements - Bluefield Daily Telegraph

Apr 09, 2025
pulisher
Apr 07, 2025

Aditx Therapeutics stock hits 52-week low at $4 amid steep decline By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

Aditxt, Inc. Discusses Appili Therapeutics Acquisition Plans - TipRanks

Apr 07, 2025
pulisher
Apr 07, 2025

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Apr 07, 2025
pulisher
Apr 07, 2025

Aditx Therapeutics stock hits 52-week low at $4 amid steep decline - Investing.com India

Apr 07, 2025
pulisher
Apr 03, 2025

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Apr 03, 2025
pulisher
Apr 02, 2025

Appili President And CEO, Don Cilla To Join Aditxt CEO, Amro Albanna For Aditxt Weekly Update On April 4, 2025 - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Appili Therapeutics CEO to Discuss Strategic Growth and Funding Initiatives - TipRanks

Apr 02, 2025
pulisher
Apr 02, 2025

Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025 - The Manila Times

Apr 02, 2025
$72.30
price down icon 0.47%
$21.48
price up icon 2.63%
$32.89
price up icon 1.26%
$27.90
price up icon 13.09%
$104.94
price up icon 2.45%
biotechnology ONC
$255.77
price up icon 0.05%
Capitalizzazione:     |  Volume (24 ore):